Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: FASEB J. 2022 May;36(5):e22328. doi: 10.1096/fj.202200251R

Figure 4. Antagonism of PPAR𝛄 offsets the anti-leukemic effect of IL-4 in AML mice.

Figure 4.

(A) Recipients of primary AML cells were dosed intra-peritoneally daily with rmIL-4 (60 μg/kg) in PBS suspension for three weeks with/without GW9662 (1mg/kg/2d, 14 doses). Euthanasia was done at the endpoint. (B) CBC counts (K/𝛍L peripheral blood) at endpoint, total WBC, EO, MO, NE, LY, BA profile of AML mice treated with IL-4 or IL-4+GW9662. (C) Spleen weights (mg) of AML mice. (D)(E) Cell counts of leukemic cells (CD45.1+) in bone marrow (D) and spleen (E) of AML mice. (F)(G) Flow cytometric analysis of total leukemic cells identified by CD45.1+ in the Lin− population of bone marrow (F) and spleen (G) of AML mice. Data shown are mean ± SEM per group, each group has at least seven biological replicates; unpaired two-tailed Student t test and outlier test were utilized; *, P < 0.05; **, P < 0.01.